Drug-induced lupus erythematosus caused by anti-tumor necrosis factor (TNF)-α therapy is considered a rare event. Although different forms of lupus erythematosus have been associated with anti-TNF-α therapy, lupus panniculitis has not been reported previously. We present a patient who developed lupus panniculitis during treatment with etanercept for psoriatic arthritis. Our patient was successfully switched to adalimumab for continued treatment of her psoriatic arthritis and experienced a simultaneous reduction in the clinical findings of lupus panniculitis. This case helps highlight the different forms of drug-induced lupus erythematosus that can occur during anti-TNF-α therapy. This case also provides additional evidence that patients with anti-TNF-α–induced lupus erythematosus can be successfully rechallenged with an alternative anti-TNF-α agent without recurrence of drug-induced lupus erythematosus.
MurrayK., DahlS.Recombinant human tumor necrosis factor receptor (p75) Fc fusion protein (TNFR: Fc) in rheumatoid arthritis. Ann Pharmacother.1997; 31: 1335–38.
6.
VassalliP.The pathophysiology of tumor necrosis factors. Annu Rev Immunol.1992; 10: 411–53.
KontoyiannisD., KolliasG.Accelerated autoimmunity and lupus nephritis in NZB mice with an engineered heterozygous deficiency in tumor necrosis factor. Eur J Immunol.2000; 30: 2038–47.
9.
Ramos-CasalsM., Brito-ZerónP., MuñozS.Autoimmune diseases induced by TNF-targeted therapies: analysis of 233 cases. Medicine (Baltimore).2007; 86: 242–51.
10.
RichezC., DumoulinC., SchaeverbekeT.Infliximab-induced chilblain lupus in a patient with rheumatoid arthritis. J Rheumatol.2005; 32: 760–1.
11.
SchneiderS., StaenderS., SchlüterB., LugerT., BonsmannG.Infliximab-induced lupus erythematosus tumidus in a patient with rheumatoid arthritis. Arch Dermatol.2006; 142: 115–6.
12.
HessE.Drug-related lupus. N Engl J Med.1988; 318: 1460–62.
13.
De BandtM., SibiliaJ., Le LoëtX.Systemic lupus erythematosus induced by anti-tumour necrosis factor α therapy: a French national survey. Arthritis Res Ther.2005; 7: R545–R51.
14.
CharlesP., SmeenkR., De JongJ., FeldmannM., MainiR.Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor α: findings in open-label and randomized placebo-controlled trials. Arthritis Rheum.2000; 43: 2383–90.
15.
SchiffM., BurmesterG., KentJ.Safety analyses of adalimumab (HUMIRA) in global clinical trials and US postmarketing surveillance of patients with rheumatoid arthritis. Ann Rheum Dis.2006; 65: 889–94.
16.
Borrás-BlascoJ., Navarro-RuizA., BorrásC., CasteráE.Adverse cutaneous reactions induced by TNF-α antagonist therapy. South Med J2009; 102: 1133–40.
17.
WetterD., DavisM.Lupus-like syndrome attributable to anti-tumor necrosis factor α therapy in 14 patients during an 8-year period at Mayo Clinic. Mayo Clinic Proc.2009; 84: 979–84.
SontheimerR., MaddisonP., ReichlinM., JordonR., StastnyP., GilliamJ.Serologic and HLA associations in subacute cutaneous lupus erythematosus, a clinical subset of lupus erythematosus. Ann Intern Med.1982; 97: 664.
29.
LoweG., HendersonC., GrauR., HansenC., SontheimerR., A systemic review of drug-induced subacute cutaneous lupus erythematosus. Br J Dermatol.2011; 164: 465–72.
30.
MarzanoA., LazzariR., PolloniI., CrostiC., FabbriP., CugnoM.Drug-induced subacute cutaneous lupus erythematosus: evidence for differences from its idiopathic counterpart. Br J Dermatol2011; 165: 335–41.
31.
WallingH., SontheimerR.Cutaneous lupus erythematosus: issues in diagnosis and treatment. Am J Clin Dermatol.2009; 10: 365–81.
32.
ErikssonC., EngstrandS., SundqvistK., Rantapaa-DahlqvistS.Autoantibody formation in patients with rheumatoid arthritis treated with anti-TNF-α. Ann Rheum Dis.2005; 64: 403–7.
33.
Remicade (infliximab). Data on File.Centocor, Nc.Malvern (PA)
34.
ZiolkowskaM., MaslinskiW.Laboratory changes on anti-tumor necrosis factor treatment in rheumatoid arthritis. Curr Opin Rheumatol2003; 15: 267–73.
35.
KeystoneE.C.Safety of biologic therapies: an update. J Rheumatol2005; 74: 8–12.
36.
Sarzi-PuttiniP.Autoantibody production in patients treated with anti-TNF-α. Expert Rev Clin Immunol.2008; 2: 275–80.
37.
MarzanoA., VezzoliR., CrostiC.Drug-induced lupus: an update on its dermatologic aspects. Lupus.2009; 18: 935–41.
38.
KocharlaL., MongeyA.Is the development of drug-related lupus a contraindication for switching from one TNF α inhibitor to another?Lupus.2009; 18: 169–72.
39.
WilliamsV., CohenP.TNF α antagonist-induced lupus-like syndrome report and review of the literature with implications for treatment with alternative TNF α antagonists. Int J Dermatol.2011; 50: 619–25.
40.
SubramanianS., YajnikV., SandsB., CullenG., KorzenikJ.Characterization of patients with infliximab-induced lupus erythematosus and outcomes after retreatment with a second anti-TNF agent. Inflamm Bowel Dis.2011; 17: 99–104.
